Sunesis, MMRC to Study Multiple Myeloma Treatment

Sunesis Pharmaceuticals and the Multiple Myeloma Research Consortium (MMRC) will evaluate Sunesis’ SNS-032 as a potential treatment of multiple myeloma.

The collaboration will examine the preclinical activity of SNS-032 in multiple myeloma-relevant models and primary disease tissue.

SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases 2, 7 and 9, which inhibits both cell cycle progression and transcription, Sunesis said.